Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels
- PMID: 16186811
- DOI: 10.1038/nbt1143
Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels
Abstract
We have engineered the Fc region of a human immunoglobulin G (IgG) to generate a mutated antibody that modulates the concentrations of endogenous IgGs in vivo. This has been achieved by targeting the activity of the Fc receptor, FcRn, which serves through its IgG salvage function to maintain and regulate IgG concentrations in the body. We show that an IgG whose Fc region was engineered to bind with higher affinity and reduced pH dependence to FcRn potently inhibits FcRn-IgG interactions and induces a rapid decrease of IgG levels in mice. Such FcRn blockers (or 'Abdegs,' for antibodies that enhance IgG degradation) may have uses in reducing IgG levels in antibody-mediated diseases and in inducing the rapid clearance of IgG-toxin or IgG-drug complexes.
Comment in
-
Antibodies in the breakdown lane.Nat Biotechnol. 2005 Oct;23(10):1232-4. doi: 10.1038/nbt1005-1232. Nat Biotechnol. 2005. PMID: 16211062 No abstract available.
Similar articles
-
Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.J Drug Target. 2014 May;22(4):269-78. doi: 10.3109/1061186X.2013.875030. Epub 2014 Jan 9. J Drug Target. 2014. PMID: 24404896 Review.
-
Antibodies in the breakdown lane.Nat Biotechnol. 2005 Oct;23(10):1232-4. doi: 10.1038/nbt1005-1232. Nat Biotechnol. 2005. PMID: 16211062 No abstract available.
-
The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.MAbs. 2015;7(2):331-43. doi: 10.1080/19420862.2015.1008353. MAbs. 2015. PMID: 25658443 Free PMC article.
-
Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies.MAbs. 2013 Jul-Aug;5(4):576-86. doi: 10.4161/mabs.24981. Epub 2013 May 29. MAbs. 2013. PMID: 23765230 Free PMC article.
-
Neonatal Fc receptor and IgG-based therapeutics.MAbs. 2011 Sep-Oct;3(5):422-30. doi: 10.4161/mabs.3.5.16983. Epub 2011 Sep 1. MAbs. 2011. PMID: 22048693 Free PMC article. Review.
Cited by
-
Insights from Fc receptor biology: a route to improved antibody reagents.MAbs. 2012 May-Jun;4(3):291-3. doi: 10.4161/mabs.20100. Epub 2012 Apr 26. MAbs. 2012. PMID: 22531437 Free PMC article.
-
Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond.Nat Rev Drug Discov. 2012 Mar 30;11(4):311-31. doi: 10.1038/nrd2909. Nat Rev Drug Discov. 2012. PMID: 22460124 Review.
-
Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration.MAbs. 2018 Oct;10(7):1111-1130. doi: 10.1080/19420862.2018.1505464. Epub 2018 Sep 12. MAbs. 2018. PMID: 30130439 Free PMC article.
-
Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn.Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2337-42. doi: 10.1073/pnas.0708960105. Epub 2008 Feb 12. Proc Natl Acad Sci U S A. 2008. PMID: 18272495 Free PMC article.
-
Synthetic Site-Specific Antibody-Ligand Conjugates Promote Asialoglycoprotein Receptor-Mediated Degradation of Extracellular Human PCSK9.ACS Chem Biol. 2023 Jul 21;18(7):1611-1623. doi: 10.1021/acschembio.3c00229. Epub 2023 Jun 27. ACS Chem Biol. 2023. PMID: 37368876 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical